ObesityPhase 3ATTAIN-CNNCT07790861
A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems
A Phase 3 study testing Orforglipron in people with Obesity and Overweight, run by Eli Lilly and Company at 13 sites in China.
Trial summary
The purpose of this study is to learn how well orforglipron works and how safe it is in Chinese adults with obesity or overweight and related health problems. Participation in this study will last about 53 weeks (about 1 year). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Obesity, Overweight
- What is being tested?
- Orforglipron
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 192 participants
- Where
- 13 sitesChina
- Study dates
- Dec 2026to Mar 2028
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Have body mass index (BMI) ≥28.0 kilograms per square meter (kg/m2) and <30 kg/m2 or ≥24.0 kg/m2 and <28 kg/m2, and at least 1 of the following weight-related comorbidities at screening:
- hypertension
- dyslipidemia
- obstructive sleep apnea
- Fatty liver
- cardiovascular disease
- Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight
Who cannot join
- Have type 1 diabetes (T1D), type 2 diabetes (T2D), or any other types of diabetes, history of ketoacidosis, or hyperosmolar state/coma
- Have a self-reported change in body weight >5 kg within 90 days prior to screening
- Had chronic or acute pancreatitis any time prior to screening
- Have family (first-degree relative) or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) syndrome
Trial locations and contacts
13 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or contact
Physicians interested in becoming principal investigators please contact contact
13 sites in 1 country
China13 sites
Sichuan Provincial People's Hospital
Chengdu, 610072
Limin Tian
Zhujiang Hospital
Guangzhou, 510280
Jia Sun
The first Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, 310003
Xiaomu Li
Zhejiang Provincial People's Hospital
Hangzhou, 310014
Xiaohong Wu
The Fourth Affiliated Hospital of Harbin Medical University
Harbin, 150001
18903602198
ZhiFeng Cheng
The Second People's Hospital of Hefei
Hefei, 230011
Yonghong Cao
Jinan Central Hospital
Jinan, 250013
Nianrong Mi
The First Affiliated Hospital of Henan University of Science &Technology
Luoyang Shi, 471003
13653880139
Hongwei Jiang
Jiangxi Provincial People's Hospital
Nanchang, 330006
13767035719
Zongyou Cheng
Nanjing First Hospital
Nanjing, 210006
Qian Li
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, 210011
18951762960
Yibing Lu
Jiangsu Province Hospital
Nanjing, 210029
18805152008
Yun Liu
Shanghai Sixth People's Hospital
Shanghai
Jian Zhou
About this study
Official title: A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once- Daily Oral Orforglipron Compared With Placebo in Chinese Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
The purpose of this study is to learn how well orforglipron works and how safe it is in Chinese adults with obesity or overweight and related health problems. Participation in this study will last about 53 weeks (about 1 year).
- Conditions
- Obesity, Overweight
- Being tested
- Orforglipron, Placebo
- Medical subject headings
- Obesity, Overweight
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
OrforglipronDrug
Also called LY3502970
Administered orally.
PlaceboDrug
Administered orally.
| Study group | Role | What they receive |
|---|---|---|
| Orforglipron | Experimental | Participants will receive orforglipron orally. Receives: Drug: Orforglipron |
| Placebo | Placebo comparator | Participants will receive placebo orally. Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean Percent Change From Baseline in Body Weight
Measured: Baseline, Week 48
Secondary outcomes (10)
Mean Change from Baseline in Waist Circumference
Measured: Baseline, Week 48
Mean Change from Baseline in Body Mass Index (BMI)
Measured: Baseline, Week 48
Mean Change from Baseline in Hemoglobin A1c (HbA1c)
Measured: Baseline, Week 48
Mean Change from Baseline in Fasting Glucose
Measured: Baseline, Week 48
Mean Percent Change from Baseline in Fasting Insulin
Measured: Baseline, Week 48
Mean Change from Baseline in Systolic Blood Pressure (SBP)
Measured: Baseline, Week 48
Mean Change from Baseline in Diastolic Blood Pressure (DBP)
Measured: Baseline, Week 48
Mean Percent Change from Baseline in Fasting non-HDL Cholesterol
Measured: Baseline, Week 48
Mean Percent Change from Baseline in Fasting Triglycerides
Measured: Baseline, Week 48
Mean Change from Baseline in Short Form Version 2 (SF-36v2) Acute Form Domain Scores
Measured: Baseline, Week 48
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Aug 2026
- Study startDec 2026 (estimated)
- Primary completionMar 2028 (estimated)
- Study completionMar 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ObesityStudies of the same condition, open and under way.
- More trials run by Eli Lilly and CompanyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 192 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Eli Lilly and Company
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Study director, Eli Lilly and Company
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07790861
- Sponsor's protocol ID
- 27942
- Other IDs
- J2A-GH-GZVC
- Acronym
- ATTAIN-CN
- Status last verified
- Oct 2026
- First submitted
- 25 Aug 2026
- Last updated
- 13 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Study at a glance
From the registry record, last updated by the sponsor on 13 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once- Daily Oral Orforglipron Compared With Placebo in Chinese Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- ClinicalTrials.gov ID
- NCT07790861
- Acronym / sponsor ID
- ATTAIN-CN / 27942
- Conditions
- Obesity, Overweight
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 192 participants (estimated)
- Lead sponsor
- Eli Lilly and CompanyIndustry (pharma, biotech, devices)
- Study start
- Dec 2026 (estimated)
- Primary completion
- Mar 2028 (estimated)
- Study completion
- Mar 2028 (estimated)
- First posted
- 27 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to learn how well orforglipron works and how safe it is in Chinese adults with obesity or overweight and related health problems. Participation in this study will last about 53 weeks (about 1 year).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Orforglipron | Experimental | Drug: OrforglipronParticipants will receive orforglipron orally. |
| Placebo | Placebo comparator | Drug: PlaceboParticipants will receive placebo orally. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Have body mass index (BMI) ≥28.0 kilograms per square meter (kg/m2) and <30 kg/m2 or ≥24.0 kg/m2 and <28 kg/m2, and at least 1 of the following weight-related comorbidities at screening:
- Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight
Key exclusion criteria (4 listed)
- Have type 1 diabetes (T1D), type 2 diabetes (T2D), or any other types of diabetes, history of ketoacidosis, or hyperosmolar state/coma
- Have a self-reported change in body weight >5 kg within 90 days prior to screening
- Had chronic or acute pancreatitis any time prior to screening
- Have family (first-degree relative) or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) syndrome
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| OrforglipronAlso: LY3502970Administered orally. | Drug | Orforglipron |
| PlaceboAdministered orally. | Drug | Placebo |
Primary outcome
Mean Percent Change From Baseline in Body Weight
Time frame: Baseline, Week 48
10 secondary outcomes
Mean Change from Baseline in Waist Circumference
Time frame: Baseline, Week 48
Mean Change from Baseline in Body Mass Index (BMI)
Time frame: Baseline, Week 48
Mean Change from Baseline in Hemoglobin A1c (HbA1c)
Time frame: Baseline, Week 48
Mean Change from Baseline in Fasting Glucose
Time frame: Baseline, Week 48
Mean Percent Change from Baseline in Fasting Insulin
Time frame: Baseline, Week 48
Mean Change from Baseline in Systolic Blood Pressure (SBP)
Time frame: Baseline, Week 48
Mean Change from Baseline in Diastolic Blood Pressure (DBP)
Time frame: Baseline, Week 48
Mean Percent Change from Baseline in Fasting non-HDL Cholesterol
Time frame: Baseline, Week 48
Mean Percent Change from Baseline in Fasting Triglycerides
Time frame: Baseline, Week 48
Mean Change from Baseline in Short Form Version 2 (SF-36v2) Acute Form Domain Scores
Time frame: Baseline, Week 48
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Oct 2026.
- Individual participant dataSharing planned: Yes. Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Related trials for Obesity
Active, not recruitingObservational study
A Longitudinal Cohort Study to Evaluate Cardiovascular Risk Factors and Disease in Haiti
Hypertension, Diabetes
Active, not recruiting
Family Functioning in Obesity Treatment for Mexican Americans
Obesity
Recruiting
Scalable TELeheaLth Cancer CARe: The STELLAR Program to Treat Cancer Risk Behaviors
Obesity, Smoking Cessation
Not yet recruitingPhase 2
Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity
Insulin Resistance, Obesity
Active, not recruiting
Optimal Digital Weight Loss Treatment for Rural Individuals
Overweight and Obesity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or contact
Physicians interested in becoming principal investigators please contact contact
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) study director
Eli Lilly and Company
13 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Orforglipron in people with Obesity and Overweight, run by Eli Lilly and Company at 13 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 13 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 13 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or (1-317-615-4559, LillyTrials@Lilly.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean Percent Change From Baseline in Body Weight (time frame: Baseline, Week 48). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Oct 2026; AzTrials last refreshed its copy on 8 Nov 2026.